These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20219270)

  • 1. Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells.
    Pédeboscq S; Gravier D; Casadebaig F; Hou G; Gissot A; De Giorgi F; Ichas F; Cambar J; Pometan JP
    Eur J Med Chem; 2010 Jun; 45(6):2473-9. PubMed ID: 20219270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
    Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
    Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
    Jung MH; Kim H; Choi WK; El-Gamal MI; Park JH; Yoo KH; Sim TB; Lee SH; Baek D; Hah JM; Cho JH; Oh CH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6538-43. PubMed ID: 19857963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
    Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
    Rheault TR; Caferro TR; Dickerson SH; Donaldson KH; Gaul MD; Goetz AS; Mullin RJ; McDonald OB; Petrov KG; Rusnak DW; Shewchuk LM; Spehar GM; Truesdale AT; Vanderwall DE; Wood ER; Uehling DE
    Bioorg Med Chem Lett; 2009 Feb; 19(3):817-20. PubMed ID: 19111461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
    Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
    Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.
    Liu Z; Klominek J
    Neoplasia; 2004; 6(6):705-12. PubMed ID: 15720796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line.
    Schenone S; Bruno O; Bondavalli F; Ranise A; Mosti L; Menozzi G; Fossa P; Donnini S; Santoro A; Ziche M; Manetti F; Botta M
    Eur J Med Chem; 2004 Nov; 39(11):939-46. PubMed ID: 15501543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
    Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
    Thapa P; Karki R; Thapa U; Jahng Y; Jung MJ; Nam JM; Na Y; Kwon Y; Lee ES
    Bioorg Med Chem; 2010 Jan; 18(1):377-86. PubMed ID: 19939682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
    Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.
    Taliani S; La Motta C; Mugnaini L; Simorini F; Salerno S; Marini AM; Da Settimo F; Cosconati S; Cosimelli B; Greco G; Limongelli V; Marinelli L; Novellino E; Ciampi O; Daniele S; Trincavelli ML; Martini C
    J Med Chem; 2010 May; 53(10):3954-63. PubMed ID: 20408530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
    Arafa RK; Nour MS; El-Sayed NA
    Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.